SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

05 فبراير 2025 09:45:03 بحسب NetDania Notify

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

04 فبراير 2025 12:22:34 بحسب NetDania Notify

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

04 فبراير 2025 09:00:05 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

30 يناير 2025 09:45:48 بحسب NetDania Notify

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

28 يناير 2025 11:23:40 بحسب NetDania Notify

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

27 يناير 2025 10:40:08 بحسب NetDania Notify

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

27 يناير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

26 نوفمبر 2024 17:00:18 بحسب Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

13 نوفمبر 2024 16:30:46 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

05 نوفمبر 2024 09:45:03 بحسب NetDania Notify

Supernus Announces Third Quarter 2024 Financial Results

04 نوفمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

31 أكتوبر 2024 16:10:46 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

30 أكتوبر 2024 15:07:03 بحسب NetDania Notify

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

21 أكتوبر 2024 16:25:48 بحسب Nasdaq GlobeNewswire

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

17 أكتوبر 2024 16:05:25 بحسب Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

10 أكتوبر 2024 17:12:14 بحسب Nasdaq GlobeNewswire

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

24 سبتمبر 2024 07:30:33 بحسب Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

19 سبتمبر 2024 16:30:44 بحسب Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

28 أغسطس 2024 16:15:26 بحسب Nasdaq GlobeNewswire

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

19 أغسطس 2024 07:00:51 بحسب Nasdaq GlobeNewswire